Cotinga Pharmaceuticals Inc COTQF

Healthcare Biotechnology

Cotinga Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company's lead clinical candidate, COTI-2, is an oral small molecule targeting p53, a tumor suppressor gene that is mutated in over 50% of all cancers, and the company's second clinical candidate, COTI-219, is a novel oral small molecule compound targeting the mutant forms of KRAS with such mutations occurring in up to 30% of all cancers.

GREY:COTQF - Post by User

Cotinga Pharmaceuticals Inc > Time to get out?

<< Previous

Bullboard Posts

Next >>

Comment by DIYGuyon Jun 23, 2017 10:59am

202 Views

Post# 26397606

RE:Time to get out?

It all depends on what the financing is done at. 12-15 gives a valuation of 18-22 million. I can't get out even I wanted to as there isn't much on the bid.

Does anyone know if the trial was set up to allow a dose decline between cohort 3 (1.0mg/kg) and cohort 4 (1.7mg/kg). I would expect you do not want a MTD too weak as it may not have the efficacy required to move to phase 2 or the dose expansion phase. I am guessing but I expect they must have a toxic result in 4th cohort and that is why it is taking so long.

Let's hope the news starts Monday, otherwise this is questionable timing like the premature PR hiring.

<< Previous

Bullboard Posts

Next >>

Abcourt Mines launches Flordin property drill campaign